Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 9/20 | 0.47 |
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381162 | 0.87 | TP53 (0.41) | LMNAHTTSMN1; SMN2HSD11B1 | |
| SCHEMBL381326 | 0.85 | EPHX2 (0.40) | CNR1CNR2SMN1; SMN2CYP3A4 | |
| SCHEMBL13031210 | 0.85 | EPHX2 (0.40) | CNR1CNR2SMN1; SMN2CYP3A4 | |
| SCHEMBL4028976 | 0.85 | HSD11B1 (0.40) | POLBCNR1HSD11B1 | |
| SCHEMBL13031209 | 0.84 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL381822 | 0.84 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL381799 | 0.84 | FAAH (0.45) | ALDH1A1LMNAHTTSMN1; SMN2CYP3A4 | |
| SCHEMBL381753 | 0.83 | PKM (0.39) | ALDH1A1LMNAHTTSMN1; SMN2HSD11B1 | |
| SCHEMBL2722387 | 0.83 | CNR2 (0.46) | ALDH1A1POLBCNR2SMN1; SMN2USP2 | |
| SCHEMBL381752 | 0.83 | PKM (0.39) | ALDH1A1LMNAHTTSMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049513-B1 | PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-01-25 | — | — | EP | claimed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | claimed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | claimed |
| EP-2049513-B1 | PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| WO-2007127901-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 141/4885POLB 2303/4885CNR1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.